ea0065p143 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019
Seejore Khyatisha
, Osborn Djoah
, Lynch Julie M
, Marples Maria
, Murray Robert D
Introduction: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that has been shown to significantly improve survival in patients with metastatic melanoma. Immune-related adverse events (irAEs) occur in some patients with increased T-cell activation, of which ipilimumab-related hypophysitis (IH) is an important treatment complication. The aim of this study is to determine the incidence of IH and characterise clinical presentat...